Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naive expansion cohort.

Masashi Kondo,Shunichi Sugawara,Toshihide Yokoyama,Toru Kumagai,Makoto Nishio,Koichi Goto,Yuichiro Ohe,Takashi Seto,Nobuyuki Yamamoto,Kentarou Kudou,Takayuki Asato,Pingkuan Zhang,Kazuhiko Nakagawa

Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naive expansion cohort.

2021

Masashi Kondo
Shunichi Sugawara
Toshihide Yokoyama
Toru Kumagai
Makoto Nishio
Koichi Goto
Yuichiro Ohe
Takashi Seto
Nobuyuki Yamamoto
Kentarou Kudou
Takayuki Asato
Pingkuan Zhang
Kazuhiko Nakagawa

9042Background: Brigatinib is a next-generation ALK inhibitor with demonstrated activity against ALK mutations. We report primary analysis results with brigatinib in Japanese patients with ALK-posi...

Keywords:

Cancer research
Brigatinib
ALK inhibitor
Medicine
Anaplastic lymphoma kinase
Cohort
Tyrosine-kinase inhibitor
non-small cell lung cancer (NSCLC)
ALK-Positive

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations